Denis Drygin - Regulus Therapeutics Chief Officer
| RGLS Stock | USD 1.61 0.03 1.83% |
Insider
Denis Drygin is Chief Officer of Regulus Therapeutics
| Age | 48 |
| Address | 4224 Campus Point Court, San Diego, CA, United States, 92121 |
| Phone | 858 202 6300 |
| Web | https://www.regulusrx.com |
Regulus Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4239) % which means that it has lost $0.4239 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7236) %, meaning that it created substantial loss on money invested by shareholders. Regulus Therapeutics' management efficiency ratios could be used to measure how well Regulus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.03 in 2024. Return On Capital Employed is likely to drop to -1.47 in 2024. At this time, Regulus Therapeutics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 4.4 M in 2024, whereas Other Current Assets are likely to drop slightly above 1.3 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert Weinberg | Verastem | N/A | |
| Alexander Klibanov | Pulmatrix | 74 | |
| CPA CPA | Cellectar Biosciences | 60 | |
| Nancy Hecox | Tenax Therapeutics | N/A | |
| Margaret MD | Pulmatrix | 67 | |
| Eliot CPA | Tenax Therapeutics | 66 | |
| Sean Flynn | Verastem | 50 | |
| Mba MBA | Verastem | 70 | |
| Aidan Curran | Pulmatrix | N/A | |
| Shane Lea | Cellectar Biosciences | N/A | |
| MBA CMA | Pulmatrix | 69 | |
| BPHARM RPh | Verastem | 63 | |
| Jonathan Pachter | Verastem | 66 | |
| Daniel Calkins | Verastem | 36 | |
| Piyush Gupta | Verastem | N/A | |
| Erin Cox | Verastem | N/A | |
| Michelle MD | Verastem | 48 | |
Management Performance
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.42 |
Regulus Therapeutics Leadership Team
Elected by the shareholders, the Regulus Therapeutics' board of directors comprises two types of representatives: Regulus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regulus. The board's role is to monitor Regulus Therapeutics' management team and ensure that shareholders' interests are well served. Regulus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regulus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph MBA, CEO Director | ||
| MS MT, VP Operations | ||
| MS MD, Senior Regulatory | ||
| Christopher JD, General VP | ||
| Crispina CPA, Chief Officer | ||
| Denis Drygin, Chief Officer | ||
| Firuz Shakoori, Head CMC | ||
| MHS MD, Head President | ||
| Daniel Penksa, Principal Accounting Officer, Controller | ||
| Edmund Lee, Vice Medicine |
Regulus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regulus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 18.63 M | ||||
| Shares Outstanding | 65.5 M | ||||
| Shares Owned By Insiders | 1.69 % | ||||
| Shares Owned By Institutions | 88.29 % | ||||
| Number Of Shares Shorted | 1.64 M | ||||
| Price To Earning | (0.69) X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 7.43 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.